dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-05-20T14:19:17Z
dc.date.accessioned2022-10-05T15:18:03Z
dc.date.available2014-05-20T14:19:17Z
dc.date.available2022-10-05T15:18:03Z
dc.date.created2014-05-20T14:19:17Z
dc.date.issued2008-04-01
dc.identifierSpectrochimica Acta Part A-molecular and Biomolecular Spectroscopy. Oxford: Pergamon-Elsevier B.V. Ltd, v. 69, n. 4, p. 1103-1109, 2008.
dc.identifier1386-1425
dc.identifierhttp://hdl.handle.net/11449/25817
dc.identifier10.1016/j.saa.2007.06.010
dc.identifierWOS:000255308500007
dc.identifier3192125098361121
dc.identifier5978908591853524
dc.identifier0000-0003-0197-7369
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3898872
dc.description.abstractThis paper describes an analytical reflectometric method that has an objective not only the industrial quality control but also to detect possible falsifications and/or adulterations of propranolol in pharmaceutical formulations. The method is based on the diffuse reflectance measurements of the colored product (III) of the spot test reaction between propranolol hydrochloride (I) and 2,6-dichloroquinone-4-chloroimide (II) using filter paper as solid support. Spot test conditions have been investigated using experimental design in order to identify and optimize the critical factors. The factors evaluated were DCQ concentration, propranolol solvent and DCQ solvent. The best reaction conditions were achieved with the addition of 30 mu L, of propranolol solution in ethanol 35% (v/v) and 30 mu L of DCQ solution at 70 mg mL(-1) in acetone, in this order. All reflectance measurements were carried out at 500 nm and the linear range was from 8.45 x 10(-4) to 8.45 x 10(-2) mol L-1 (r= 0.998). The limit of detection was 1.01 x 10(-4) mol L-1. No interference was observed from the assessed excipients and drugs. The method was applied to determine propranolol in commercial brands of pharmaceuticals. The results obtained by the proposed method were favorably compared with those given by the British Pharmacopoeia procedure. (C) 2007 Elsevier B.V. All rights reserved.
dc.languageeng
dc.publisherPergamon-Elsevier B.V. Ltd
dc.relationSpectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy
dc.relation25798
dc.relation32204
dc.relation70078
dc.relation2.880
dc.relation0,648
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.subjectdiffuse reflectance spectroscopy
dc.subjectpropranolol
dc.subjectspot test
dc.subject2,6-dichloroquinone-4-chloroimide
dc.subjectexperimental design
dc.titleDetection of propranolol in pharmaceutical formulations by diffuse reflectance spectroscopy
dc.typeArtigo


Este ítem pertenece a la siguiente institución